Middle East Fertility Society Journal
Volume 16, Issue 4 , Pages 248-253 , December 2011

Progestin potency – Assessment and relevance to choice of oral contraceptives

Received 19 June 2011 ,Accepted 8 August 2011.

References 

  1. Dorflinger LJ. Relative potency of progestins used in oral contraceptives. Contraception. 1985;31:557–570
  2. Phillips A, Demarest K, Hahn DW, Wong F, McGuire JC. Progestational and androgenic receptor binding affinities and in vivo activities of norgestimate and other progestins. Contraception. 1990;41:399–410
  3. Rebar RW, Zeserson K. Characteristics of the new progestogens in combination oral contraceptives. Contraception. 1991;44:1–10
  4. Phillips A, Hahn DW, McGuire JL. Preclinical evaluation of norgestimate, a progestin with minimal androgenic activity. Am J Obstet Gynecol. 1992;167:1191–1202
  5. Phillips A, Hahn DW, Klimek S, McGuire JL. A comparison of the potencies and activities of progestogens used in contraceptives. Contraception. 1987;36:181–192
  6. Muhn P, Krattenmacher R, Beier S, Elger W, Schillinger E. Drospirenone: a novel progestogen with antimineralocorticoid and antiandrogenic activity. Contraception. 1995;51:99–110
  7. Upmalis D, Phillips A. Receptor blinding and in vivo activities of the new progestins. J Soc Obstet Gynecol Canada. 1991;13:35S–39S
  8. Fotherby K. Potency and pharmacokinetics of gestagens. Contraception. 1990;41:533–550
  9. Dickey RP. Managing contraceptive pill patients. 12th ed.. Dallas, TX: EMIS; 2004;
  10. Stanczyk FZ. All progestins are not created equal. Steroids. 2003;68:879–890
  11. Stanczyk FZ. Pharmacokinetics and potency of progestins used for hormone replacement therapy and contraception. Rev Endoc Metab Dis. 2002;3:211–224
  12. Carr BR. Uniqueness of oral contraceptive progestins. Contraception. 1998;58:235–275
  13. Wiegratz I, Kuhl H. Metabolic and clinical effects of progestagens. Eur J Contracept Reprod Health Care. 2006;11:153–161
  14. Sitruk-Ware R. New progestagens for contraceptive use. Hum Reprod Update. 2005;12:169–178
  15. Kulier R, Helmerhorst FM, Maitra M, Gulmezoglu M. Effectiveness and acceptability of progestogens in combined oral contraceptives a systematic review. Reprod Health. 2004;1:1–9
  16. Oelkers W. Drospirone – a new progestogen with antimineralocorticoid activity, resembling natural progesterone. Eur J Contracept Reprod Health Care. 2000;5(Suppl 3):17–24
  17. Sitruk-Ware R. Pharmacology of different progestogens: the special case of drospirenone. Climacteric. 2005;8(Suppl 3):4–12
  18. Ferin J. Orally active progestational compounds. Human studies: effects on the utero–vaginal tract. In: International encyclopaedia of pharmacology and therapeutics. vol. II:Oxford: Pergamon Press; 1972;p. 245–274[Chapter 30, Section 48]
  19. Dickey RP, Berger GS. Persistent amenorrhoea and galactorrhoea. In:  Givens JR editors. Clinical use of sex steroids. Chicago: Yearbook Medical Publishing; 1980;p. 329–338
  20. Grant ECG. Hormone balance of oral contraceptives. J Obstet Gynaec Brit Cwlth. 1967;74:908–918
  21. King RJB, Whitehead MI. Assessment of the potency of orally administered progestins in women. Fertil Steril. 1986;46:1062–1066
  22. Byrjalsen I, Bjarnson NH, Christiansen C. Progetational effects of combinations of gestodene on the postmenopausal endometrium during hormone replacement therapy. Am J Obstet Gynecol. 1999;180:539–549
  23. Greenblatt RB, Jung EC, Bartfield WE. A new test for the efficacy of progestational compounds. Ann NY Acad Sci. 1958;77:406–409
  24. Swyer GIM. Determination of progestational potency: a review. J Roy Soc Med. 1984;77:406–409
  25. Goldstuck ND. Potency of progestogens in oral contraceptive formulations containing 30 to 35g ethinyl estradiol assessed by delay of menses. J Soc Obstet Gynecol Can. 1997;19:181–185
  26. Goldzieher JW. Use and misuse of the term potency with respect to oral contraceptives. J. Reprod Med. 1986;31:5335–5375
  27. Greeblatt RB. Progestational agents in clinical practice. Med Sci. 1967;37–49
  28. Swyer GIM, Little V. Clinical assessment of relative potency of progestagens. J. Reprod Fert. 1968;5:635–685
  29. Swyer GIM, Sebok L, Barns DF. Determination of the relative potency of some progestogens in the human. Proc R Soc Med. 1960;53:435–436
  30. Swyer GIM, Little V. Actions and uses of orally active progestational steroids. Proc Roy Soc Med. 1962;55:861–863
  31. Swyer GIM. Potency of progestogens in oral contraceptives – further delay of menses data. Contraception. 1982;26:23–27
  32. Gillmer MDG. Progestogen potency in oral contraceptive pills. Am J Obstet Gynecol. 1987;157:1048–1052
  33. Berger GS, Talwar PP. Oral contraceptive potencies and side effects. Obstet Gynecol. 1978;51:545–657
  34. Pike MC, Henderson BE, Krailo MD, Duke A, Roy S. Breast cancer in young women and use of oral contraceptives: possible modifying effect of formulation and age at use. Lancet. 1983;2:926–930
  35. Maxwell GL, Schildkraut JM, Calingaert B, et al. Progestin and estrogen potency of combination oral contraceptives and endometrial cancer risk. Gynecol Oncol. 2006;103:535–540
  36. Voight LF, Deng Q, Weiss NS. Recency, duration, and progestin content of oral contraceptives in relation to the incidence of endometrial cancer (Washington, USA). Cancer Causes Control. 1994;5:227–233
  37. Piper JM, Kennedy DL. Oral contraceptives in the United States: trends in content and potency. Int J Epid. 1987;16:215–221
  38. Henderson BE, Casagrande JT, Pike MC, Marsh T, Rosario I, Duke A. The epidemiology of endometrial cancer in young women. Br J Cancer. 1983;47:749–756
  39. Lurie G, Thompson P, McDuffie KE, Carney ME, Terada KY, Goodman MT. Association of estrogen and progestin potency of oral contraceptives with ovarian carcinoma risk. Obstet Gynecol. 2007;109:597–607
  40. Shildkraut JM, Calingaert B, Marchbanks P, Noorman PG, Rodriguez GC. Impact of progestin and estrogen potency in oral contraceptives on ovarian cancer risk. J Nat Cancer Institute. 2002;96:32–38
  41. Goldzieher JW. Pharmacology of contraceptive steroids: a brief review. Am J Obstet Gynecol. 1989;160:1260–1264
  42. Goldzieher JW, Stanczyk FZ. Oral contraceptives and individual variability of circulating levels of ethinyl estradiol and progestins. Contraception. 2008;78:4–9
  43. Dickey RP, Stone SC. Progestational potency of oral contraceptives. Obstet Gynecol. 1976;47:106–112
  44. Runnebaum B, Rabe T. New progestogens in oral contraceptives. Am J Obstet Gynecol. 1987;157:1059–1063

PII: S1110-5690(11)00077-X

doi: 10.1016/j.mefs.2011.08.006

Middle East Fertility Society Journal
Volume 16, Issue 4 , Pages 248-253 , December 2011

Article Tools